Literature DB >> 26929386

Using lessons from breast, cervical, and colorectal cancer screening to inform the development of lung cancer screening programs.

Katrina Armstrong1, Jane J Kim2, Ethan A Halm3,4, Rachel M Ballard5, Mitchell D Schnall6.   

Abstract

Multiple advisory groups now recommend that high-risk smokers be screened for lung cancer by low-dose computed tomography. Given that the development of lung cancer screening programs will face many of the same issues that have challenged other cancer screening programs, the National Cancer Institute-funded Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) consortium was used to identify lessons learned from the implementation of breast, cervical, and colorectal cancer screening that should inform the introduction of lung cancer screening. These lessons include the importance of developing systems for identifying and recruiting eligible individuals in primary care, ensuring that screening centers are qualified and performance is monitored, creating clear communication standards for reporting screening results to referring physicians and patients, ensuring follow-up is available for individuals with abnormal test results, avoiding overscreening, remembering primary prevention, and leveraging advances in cancer genetics and immunology. Overall, this experience emphasizes that effective cancer screening is a multistep activity that requires robust strategies to initiate, report, follow up, and track each step as well as a dynamic and ongoing oversight process to revise current screening practices as new evidence regarding screening is created, new screening technologies are developed, new biological markers are identified, and new approaches to health care delivery are disseminated. Cancer 2016;122:1338-1342.
© 2016 American Cancer Society. © 2016 American Cancer Society.

Entities:  

Keywords:  implementation; lung cancer; primary care; quality; screening

Mesh:

Year:  2016        PMID: 26929386      PMCID: PMC4840047          DOI: 10.1002/cncr.29937

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  29 in total

1.  ACR CT accreditation program and the lung cancer screening program designation.

Authors:  Ella A Kazerooni; Mark R Armstrong; Judith K Amorosa; Dina Hernandez; Lawrence A Liebscher; Hrudaya Nath; Michael F McNitt-Gray; Eric J Stern; Pamela A Wilcox
Journal:  J Am Coll Radiol       Date:  2014-11-20       Impact factor: 5.532

2.  Molecular profiling of premalignant lesions in lung squamous cell carcinomas identifies mechanisms involved in stepwise carcinogenesis.

Authors:  Aik T Ooi; Adam C Gower; Kelvin X Zhang; Jessica L Vick; Longsheng Hong; Brian Nagao; W Dean Wallace; David A Elashoff; Tonya C Walser; Steven M Dubinett; Matteo Pellegrini; Marc E Lenburg; Avrum Spira; Brigitte N Gomperts
Journal:  Cancer Prev Res (Phila)       Date:  2014-03-11

3.  An official American Thoracic Society/American College of Chest Physicians policy statement: implementation of low-dose computed tomography lung cancer screening programs in clinical practice.

Authors:  Renda Soylemez Wiener; Michael K Gould; Douglas A Arenberg; David H Au; Kathleen Fennig; Carla R Lamb; Peter J Mazzone; David E Midthun; Maryann Napoli; David E Ost; Charles A Powell; M Patricia Rivera; Christopher G Slatore; Nichole T Tanner; Anil Vachani; Juan P Wisnivesky; Sue H Yoon
Journal:  Am J Respir Crit Care Med       Date:  2015-10-01       Impact factor: 21.405

4.  Unifying screening processes within the PROSPR consortium: a conceptual model for breast, cervical, and colorectal cancer screening.

Authors:  Elisabeth F Beaber; Jane J Kim; Marilyn M Schapira; Anna N A Tosteson; Ann G Zauber; Ann M Geiger; Aruna Kamineni; Donald L Weaver; Jasmin A Tiro
Journal:  J Natl Cancer Inst       Date:  2015-05-07       Impact factor: 13.506

5.  Overdiagnosis in low-dose computed tomography screening for lung cancer.

Authors:  Edward F Patz; Paul Pinsky; Constantine Gatsonis; Jorean D Sicks; Barnett S Kramer; Martin C Tammemägi; Caroline Chiles; William C Black; Denise R Aberle
Journal:  JAMA Intern Med       Date:  2014-02-01       Impact factor: 21.873

6.  Transforming Cancer Prevention through Precision Medicine and Immune-oncology.

Authors:  Thomas W Kensler; Avrum Spira; Judy E Garber; Eva Szabo; J Jack Lee; Zigang Dong; Andrew J Dannenberg; William N Hait; Elizabeth Blackburn; Nancy E Davidson; Margaret Foti; Scott M Lippman
Journal:  Cancer Prev Res (Phila)       Date:  2016-01

7.  Application of SNP microarrays to the genome-wide analysis of chromosomal instability in premalignant airway lesions.

Authors:  Ichiro Nakachi; Jessica L Rice; Christopher D Coldren; Michael G Edwards; Robert S Stearman; Steven C Glidewell; Marileila Varella-Garcia; Wilbur A Franklin; Robert L Keith; Marina T Lewis; Bifeng Gao; Daniel T Merrick; York E Miller; Mark W Geraci
Journal:  Cancer Prev Res (Phila)       Date:  2013-12-17

8.  Current cigarette smoking among adults - United States, 2005-2014.

Authors:  Ahmed Jamal; David M Homa; Erin O'Connor; Stephen D Babb; Ralph S Caraballo; Tushar Singh; S Sean Hu; Brian A King
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-11-13       Impact factor: 17.586

9.  Implementation of Lung Cancer Screening in the United States: Changing Trends Based on a Survey of Society of Thoracic Radiology Members.

Authors:  Jan M Eberth; Erica Sercy
Journal:  J Thorac Imaging       Date:  2015-11       Impact factor: 3.000

10.  Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA.

Authors:  Evgeny Izumchenko; Xiaofei Chang; Mariana Brait; Elana Fertig; Luciane T Kagohara; Atul Bedi; Luigi Marchionni; Nishant Agrawal; Rajani Ravi; Sian Jones; Mohammad O Hoque; William H Westra; David Sidransky
Journal:  Nat Commun       Date:  2015-09-16       Impact factor: 14.919

View more
  7 in total

1.  A Systematic Review of Repeat Fecal Occult Blood Tests for Colorectal Cancer Screening.

Authors:  Caitlin C Murphy; Ahana Sen; Bianca Watson; Samir Gupta; Helen Mayo; Amit G Singal
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-11-18       Impact factor: 4.254

2.  Implementing Decision Coaching for Lung Cancer Screening in the Low-Dose Computed Tomography Setting.

Authors:  Lisa M Lowenstein; Myrna Cobos Barco Godoy; Jeremy J Erasmus; Zineb Zirari; Alina Bennett; Viola B Leal; Ashley J Housten; Robert J Volk
Journal:  JCO Oncol Pract       Date:  2020-03-24

Review 3.  Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Douglas E Wood; Ella A Kazerooni; Scott L Baum; George A Eapen; David S Ettinger; Lifang Hou; David M Jackman; Donald Klippenstein; Rohit Kumar; Rudy P Lackner; Lorriana E Leard; Inga T Lennes; Ann N C Leung; Samir S Makani; Pierre P Massion; Peter Mazzone; Robert E Merritt; Bryan F Meyers; David E Midthun; Sudhakar Pipavath; Christie Pratt; Chakravarthy Reddy; Mary E Reid; Arnold J Rotter; Peter B Sachs; Matthew B Schabath; Mark L Schiebler; Betty C Tong; William D Travis; Benjamin Wei; Stephen C Yang; Kristina M Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2018-04       Impact factor: 11.908

Review 4.  Recommendations for lung cancer screening in Southern Africa.

Authors:  Coenraad F N Koegelenberg; Shane Dorfman; Ivan Schewitz; Guy A Richards; Shaun Maasdorp; Clifford Smith; Keertan Dheda
Journal:  J Thorac Dis       Date:  2019-09       Impact factor: 2.895

5.  Trends in lung cancer screening in the United States, 2016-2017.

Authors:  Ikenna C Okereke; Shawn Nishi; Jie Zhou; James S Goodwin
Journal:  J Thorac Dis       Date:  2019-03       Impact factor: 2.895

Review 6.  Possible role of circulating tumor cells in early detection of lung cancer.

Authors:  Cristina Poggiana; Elisabetta Rossi; Rita Zamarchi
Journal:  J Thorac Dis       Date:  2020-07       Impact factor: 3.005

7.  Validation of a prognostic score for hidden cancer in unprovoked venous thromboembolism.

Authors:  Luis Jara-Palomares; Remedios Otero; David Jimenez; Juan Manuel Praena-Fernandez; Carme Font; Conxita Falga; Silvia Soler; David Riesco; Peter Verhamme; Manuel Monreal
Journal:  PLoS One       Date:  2018-03-20       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.